MX2018015656A - Compuestos heterociclicos como antibacterianos. - Google Patents
Compuestos heterociclicos como antibacterianos.Info
- Publication number
- MX2018015656A MX2018015656A MX2018015656A MX2018015656A MX2018015656A MX 2018015656 A MX2018015656 A MX 2018015656A MX 2018015656 A MX2018015656 A MX 2018015656A MX 2018015656 A MX2018015656 A MX 2018015656A MX 2018015656 A MX2018015656 A MX 2018015656A
- Authority
- MX
- Mexico
- Prior art keywords
- antibacterials
- heterocyclic compounds
- compounds
- tuberculosis
- medicaments
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 229940088710 antibiotic agent Drugs 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16174719 | 2016-06-16 | ||
| PCT/EP2017/064652 WO2017216281A1 (en) | 2016-06-16 | 2017-06-15 | Heterocyclic compounds as antibacterials |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018015656A true MX2018015656A (es) | 2019-03-14 |
Family
ID=56132837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015656A MX2018015656A (es) | 2016-06-16 | 2017-06-15 | Compuestos heterociclicos como antibacterianos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11179396B2 (enExample) |
| EP (1) | EP3472158A1 (enExample) |
| JP (1) | JP2019518046A (enExample) |
| KR (1) | KR20190017948A (enExample) |
| CN (1) | CN109476657A (enExample) |
| AU (1) | AU2017286368B2 (enExample) |
| BR (1) | BR112018076126A2 (enExample) |
| CA (1) | CA3026010A1 (enExample) |
| EA (1) | EA201990043A1 (enExample) |
| MA (1) | MA45377A (enExample) |
| MX (1) | MX2018015656A (enExample) |
| WO (1) | WO2017216281A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220339T1 (hr) | 2015-07-02 | 2022-05-13 | Janssen Sciences Ireland Unlimited Company | Antibakterijski spojevi |
| IL257743B (en) | 2015-09-17 | 2022-08-01 | Marvin J Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
| AU2017286368B2 (en) | 2016-06-16 | 2021-02-25 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| EP3589323B1 (en) | 2017-03-01 | 2024-04-03 | Janssen Sciences Ireland Unlimited Company | Combination therapy for the treatment of tuberculosis |
| PL3684767T3 (pl) | 2017-09-22 | 2024-10-14 | Jubilant Epipad LLC | Związki heterocykliczne jako inhibitory pad |
| PL3697785T3 (pl) | 2017-10-18 | 2023-08-07 | Jubilant Epipad LLC | Związki imidazopirydynowe jako inhibitory pad |
| AU2018362046B2 (en) | 2017-11-06 | 2023-04-13 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| SI3704120T1 (sl) | 2017-11-24 | 2024-07-31 | Jubilant Episcribe Llc | Heterociklične spojine kot inhibitorji prmt5 |
| EP3765453A1 (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| TWI861208B (zh) | 2019-09-10 | 2024-11-11 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物 |
| CN114423758B (zh) | 2019-09-13 | 2025-05-27 | 爱尔兰詹森科学公司 | 抗细菌化合物 |
| CN114746089A (zh) * | 2019-09-26 | 2022-07-12 | 结核病药物开发全球联盟公司 | 噻唑甲酰胺化合物及其用于治疗分枝杆菌感染的用途 |
| WO2021063915A1 (en) | 2019-09-30 | 2021-04-08 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| EP4038067A1 (en) | 2019-09-30 | 2022-08-10 | Janssen Sciences Ireland Unlimited Company | 4-quinolinone antibacterial compounds |
| AU2022237769A1 (en) | 2021-03-16 | 2023-11-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022194905A1 (en) | 2021-03-17 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| EP4308579A1 (en) * | 2021-03-17 | 2024-01-24 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| KR20240090864A (ko) | 2021-10-28 | 2024-06-21 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 세균성 감염의 치료에 사용하기 위한 이미다조피리딘 아미드 및 관련 화합물 |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996015130A1 (en) | 1994-11-15 | 1996-05-23 | Pharmacia + Upjohn Company | Bicyclic oxazine and thiazine oxazolidinone antibacterials |
| DE69614847T2 (de) | 1995-05-11 | 2002-04-04 | Pharmacia & Upjohn Co., Kalamazoo | Spirocyclische und bicyclische diazinyl- und carbazinyloxazolidinone |
| EA008937B1 (ru) | 2002-07-25 | 2007-10-26 | Янссен Фармацевтика Н.В. | Производные хинолина и их применение в качестве микобактериальных ингибиторов |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| MA27360A1 (fr) | 2004-11-23 | 2005-06-01 | Brahim Bennani | Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux |
| US20100298314A1 (en) | 2006-12-20 | 2010-11-25 | Schering Corporation | Novel jnk inhibitors |
| TW200901969A (en) | 2007-06-06 | 2009-01-16 | Smithkline Beecham Corp | Chemical compounds |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| CN101965353B (zh) | 2008-03-26 | 2014-12-17 | 丹诺医药(苏州）有限公司 | 共价连接到取代苯基噁唑烷酮的双环硝基咪唑类 |
| AU2009294850B2 (en) | 2008-09-22 | 2015-07-02 | Oregon Health & Science University | Methods for detecting a Mycobacterium tuberculosis infection |
| US20120040951A1 (en) | 2008-12-30 | 2012-02-16 | Claudio Chuaqui | Heteroaryl compounds useful as raf kinase inhibitors |
| EP3257854A1 (en) | 2009-11-05 | 2017-12-20 | University of Notre Dame du Lac | Imidazo[1,2-a]pyridine compounds, synthesis thereof, and methods of using same |
| MX345762B (es) | 2010-03-18 | 2017-02-15 | Pasteur Institut Korea | Compuestos antiinfecciosos. |
| KR102104125B1 (ko) | 2011-04-21 | 2020-05-29 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| AP2014007493A0 (en) | 2011-09-01 | 2014-03-31 | Irm Llc | Compounds and compositions as C-KIT kinase inhibitors |
| RS55807B1 (sr) | 2012-03-02 | 2017-08-31 | Genentech Inc | Amido spirociklični amidni i sulfonamidni derivati |
| KR101918469B1 (ko) | 2012-06-04 | 2018-11-15 | 한국화학연구원 | 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| EP2875029B8 (en) * | 2012-07-18 | 2021-12-15 | University of Notre Dame du Lac | 5,5-heteroaromatic anti-infective compounds |
| CA2879623C (en) * | 2012-08-10 | 2021-11-02 | Janssen Sciences Ireland Uc | Fused bicyclic azole heterocycle as inhibitors of the enzyme fabi |
| KR101650716B1 (ko) | 2012-11-22 | 2016-08-24 | 한국화학연구원 | 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물 |
| WO2015014993A2 (en) * | 2013-08-02 | 2015-02-05 | Institut Pasteur Korea | Anti-infective compounds |
| KR101564425B1 (ko) | 2013-11-26 | 2015-10-30 | 한국화학연구원 | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 |
| CN105524058B (zh) | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| CN107249691A (zh) | 2014-11-03 | 2017-10-13 | 加利福利亚大学董事会 | 用于肺结核治疗的多药疗法 |
| HRP20220339T1 (hr) | 2015-07-02 | 2022-05-13 | Janssen Sciences Ireland Unlimited Company | Antibakterijski spojevi |
| AU2017286368B2 (en) | 2016-06-16 | 2021-02-25 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| MA45375A (fr) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Co | Composés hétérocycliques utilisés en tant qu'agents antibacteriens |
| EP3589323B1 (en) | 2017-03-01 | 2024-04-03 | Janssen Sciences Ireland Unlimited Company | Combination therapy for the treatment of tuberculosis |
-
2017
- 2017-06-15 AU AU2017286368A patent/AU2017286368B2/en not_active Ceased
- 2017-06-15 WO PCT/EP2017/064652 patent/WO2017216281A1/en not_active Ceased
- 2017-06-15 MX MX2018015656A patent/MX2018015656A/es unknown
- 2017-06-15 CA CA3026010A patent/CA3026010A1/en not_active Abandoned
- 2017-06-15 EA EA201990043A patent/EA201990043A1/ru unknown
- 2017-06-15 CN CN201780037229.4A patent/CN109476657A/zh active Pending
- 2017-06-15 KR KR1020197000960A patent/KR20190017948A/ko not_active Ceased
- 2017-06-15 MA MA045377A patent/MA45377A/fr unknown
- 2017-06-15 JP JP2018565675A patent/JP2019518046A/ja active Pending
- 2017-06-15 US US16/309,725 patent/US11179396B2/en not_active Expired - Fee Related
- 2017-06-15 EP EP17729877.5A patent/EP3472158A1/en not_active Withdrawn
- 2017-06-15 BR BR112018076126-5A patent/BR112018076126A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190017948A (ko) | 2019-02-20 |
| AU2017286368A1 (en) | 2018-12-06 |
| CN109476657A (zh) | 2019-03-15 |
| EA201990043A1 (ru) | 2019-05-31 |
| CA3026010A1 (en) | 2017-12-21 |
| US11179396B2 (en) | 2021-11-23 |
| US20190134046A1 (en) | 2019-05-09 |
| BR112018076126A2 (pt) | 2019-03-26 |
| MA45377A (fr) | 2019-04-24 |
| AU2017286368B2 (en) | 2021-02-25 |
| EP3472158A1 (en) | 2019-04-24 |
| JP2019518046A (ja) | 2019-06-27 |
| WO2017216281A1 (en) | 2017-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018015656A (es) | Compuestos heterociclicos como antibacterianos. | |
| ZA201708692B (en) | Antibacterial compounds | |
| MX2018015657A (es) | Compuestos heterociclico como antibacterianos. | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| NZ736665A (en) | Heterocyclic amides as kinase inhibitors | |
| MY187540A (en) | Compounds active towards bromodomains | |
| SG10201811454WA (en) | Materials and methods for controlling infections | |
| MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
| MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
| PH12019502002A1 (en) | Combination theraphy | |
| PH12014501991B1 (en) | Phenicol antibacterials | |
| AU2015299431B2 (en) | Pyrrolidinone derivatives as metAP-2 inhibitors | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX2021010886A (es) | Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
| MX370412B (es) | Compuesto antimicotico. | |
| PH12015501038A1 (en) | Inhibitors of iap | |
| PH12016501865A1 (en) | Pyridine-2-amides useful as cb2 agonists | |
| GEP20186893B (en) | Pyrazines modulators of gpr6 | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MX2016004078A (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih). | |
| MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
| MX2022003814A (es) | Compuestos antibacterianos de 4-quinolinona. | |
| MX2022003816A (es) | Compuestos antibacterianos. | |
| UA93017U (uk) | Препарат "нановулін-врх" | |
| HK1240079A1 (en) | Method for treating hyperhidrosis |